Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.

Int J Mol Sci · 2023 · PMC10144688 · PMID 37108802

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the Checkmate 040 trial, increased CD3+/CD8+ tumor-infiltrating T cells of nivolumab-treated HCC patients showed a trend toward survival prolongation, but was not significant ( p = 0.08) [ 162 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

In this study, the objective response rate (ORR) was 19% in patients with <1% PD-L1 expression in tumor biopsy samples and 26% in patients with ≥1% PD-L1 expression in tumor biopsy samples using a PD-L1 IHC 28-8 pharmDx assay; however, this difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.